Vaccines developed by Aivita Biomedical use a patient's own blood to attack cancer and Covid-19. But the company also offers a consumer skin-care product that it plans to begin selling more widely.
AiVita is developing an immunotherapy for solid tumors, which may soon enter phase II clinical trials for ovarian cancer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.